Developing life-changing therapies for complex neurological disorders with axonal dysfunction

Therapeutic Focus

Toward a Cure for neuromuscular and neurodegenerative disorders

We’re Augustine Therapeutics, a biotech company driven by a clear purpose: to transform the lives of patients suffering from severe peripheral and central nervous system disorders, in particular the rare hereditary disorder Charcot-Marie-Tooth (CMT), but also other axonal degeneration induced by chemotherapy (CIPN). Our driving force is to advance the knowledge of axonal protection, regeneration, and remyelination and its translation into effective therapies for patients with unmet medical needs.

We are developing  anovel generation of unique samll molecule therapeutics that can achieve reinnervation, aiming to slow down and even reverse the disease and provide significant relief for patients affected by axonopathies. Our assets also have potential therapeutic applications in cardiometabolism, inflammatory and autoimmune diseases.

Learn more about our therapeutic focus



We currently have multiple programs in development: our lead project targeting peripherally restricted and selective HDAC6i for CMT and CIPN is advancing into in regulatory preclinical development, while our second and third program are in precinical discovery stage targeting our brain penetrant and peripheral-restricted selective HDAC6i for ALS and cardio-metabolism, respectively.

About Us

Founded in 2019, Augustine Therapeutics is a biotech company in Leuven, Belgium.

The company is rooted in the groundbreaking research of the laboratory of Professor Ludo Van Den Bosch from the VIB-KU Leuven Center for Brain and Disease Research.

Supported by an advisory board of leading international experts, our experienced team develops innovative, best-in-class therapeutics to address the great unmet need for the treatment of neuromuscular and neurodegenerative disorders.

More about us

Sylvain Celanire, PhD - Chief Executive Officer
Christophe Van Vaeck, PhD - Chief Financial Officer
Frederik Rombouts, PhD - Vice President, Drug Discovery
Jonathan van Eyll, PhD - Head of Pharmacology
Cédric Szyndralewiez, MSc - Head of Non-Clinical and Early Development


Sylvain has more than 20 years of experience as an executive director, entrepreneur, and advisor in the biotech/pharma sector


Christophe with more than 20 years of operational and strategic experience in the Life Sciences financial community


Frederik has 22 years of drug discovery research and development experience in the neuroscience and oncology therapeutic areas


Jonathan has more than 18 years of experience in advancing various therapeutic modalities in Neuroscience drug discovery research through translational pharmacoclogy and bioinformatics


Cédric has 25 years of experience in preclincial research and early clinical development in the therapeutic areas of inflammation, neurology, fibrosis and oncology

All our team members | soon production